Non-Hodgkin Lymphoma Treatment Statistics and Results
Learn More About Treatment Results for Non-Hodgkin Lymphoma: Chat with Us | Email Us
At CTCA, we understand that everyone’s cancer journey is different. Yet, a common need for cancer patients and their families is information. Few hospitals or care facilities publish their treatment results, patient survival statistics, or information about the quality of life patients experience in their care. We understand that this information can help you make informed decisions about where to go for treatment.
Currently, CTCA publishes patient survival rate information for 10 cancers we treat. Although we have not yet compiled our results for Non-Hodgkin Lymphoma cancer, our cancer experts have treated numerous Non-Hodgkin Lymphoma cancer cases using our whole-person care model, including advanced technologies combined with supportive therapies.
Until we have such published CTCA results, we will continue to provide survival results for Non-Hodgkin Lymphoma cancer experienced at treatment centers in the U.S. generally. The following results were published in the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database:
Cancer of the Non-Hodgkin Lymphoma – SEER Results
5 Year Relative Survival Rates for Year of Diagnosis between 1999 and 2005: 68.6%*
This information is taken directly from the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) website, specifically from the annual SEER Cancer Statistics Review (CSR).
http://seer.cancer.gov/csr/1975_2006/browse_csr.php
* Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2005. The remaining 13 SEER Areas contribute cases for the entire period 1999-2005. Rates are based on follow-up of patients into 2006.
*Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2003-2005: 0-1 year survival), (2002-2004: 1-2 year survival), (2001-2003: 2-3 year survival), (2000-2002: 3-4 year survival), (1999-2001: 4-5 years survival).
